Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
VTR Ventas Inc
LTC LTC Properties Inc
CNK Cinemark Holdings Inc
TITN Titan Machinery Inc
AHL-C Aspen Insurance Holdings Ltd
EVBN Evans Bancorp Inc
CTXS Citrix Systems Inc
RY Royal Bank of Canada
MCIOF MCI Onehealth Technologies Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.

Price
Delayed
$8.30
Day's Change
-0.82 (-8.99%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.29
Day's Low
8.20
Volume
(Light)

Today's volume of 207,513 shares is on pace to be much lighter than LGVN's 10-day average volume of 384,047 shares.

207,513

Company Profile

Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
128.10x
Price/Book (MRQ)
4.46x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

April 2022
Current Month
315.1K
Previous Month
658.7K
Percent of Float
7.20%
Days to Cover
0.1193 Days

Share Information

LGVN is in a share class of common stock
Float
4.6M
Shares Outstanding
20.9M
Institutions Holding Shares
12
11.38%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

No cash flow information available.

Company Officers

No company officers listed.

Address

Insider Trading

During the most recent quarter, 20K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.